GridAI Deal Delays Q3 Filing and Sparks 25% Plunge in Entero Shares
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Entero Therapeutics, Inc. (Nasdaq: ENTO) is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company is headquartered in Boca Raton, Florida, with clinical operations in Hayward, California. Entero’s programs aim to address needs in celiac disease, gastroparesis, exocrine pancreatic insufficiency, and related disorders.
Corporate Structure
Entero Therapeutics is publicly traded on the Nasdaq Capital Market under the ticker ENTO. The company was founded in 2014 and employs between 11 and 50 professionals across research, clinical development, and corporate functions. Its leadership team includes executives with experience in biopharma, capital markets, and corporate governance.
| Metric | Detail |
|---|---|
| Exchange | Nasdaq Capital Market (ENTO) |
| Employees | 11–50 |
| Founded | 2014 |
| Headquarters | Boca Raton, FL |
| Clinical Operations | Hayward, CA |
Biopharmaceutical by Melany @ tuinfosalud.com
Recent Developments and News
- May 16, 2024: Entero Therapeutics announced its rebranding from First Wave BioPharma and adoption of the ENTO ticker, effective May 17, 2024. This change coincided with a planned Phase 3 study for latiglutenase.
- August 14, 2025: The board of directors and shareholders approved a 1-for-3 reverse stock split, effective August 18, 2025, to comply with Nasdaq’s minimum bid price requirement of $1.00 per share.
- November 6, 2025: The company filed a Form 8-K under Items 8.01 and 9.01, disclosing certain corporate events and changes (see filing link for details).
- September 29, 2025: Renaissance Technologies LLC and Renaissance Technologies Holdings Corp. reported beneficial ownership of 86,400 shares, representing 5.44% of outstanding common stock, in a Schedule 13G filed on November 13, 2025.
- November 17, 2025: Entero filed an NT 10-Q, notifying the SEC of a delay in its Q3 2025 Form 10-Q. The delay is due to a review of the accounting treatment related to the acquisition of GridAI Corp.; the company expects to complete and file the report within five calendar days of the original due date.
Financial and Strategic Analysis
At market close on November 19, 2025, ENTO shares traded at $2.87, reflecting a 25.34% decline on a volume of 200,286 shares. The August 18 reverse split was implemented to maintain compliance with Nasdaq listing requirements, while the pending completion of the Q3 10-Q indicates ongoing accounting reviews associated with the GridAI acquisition. The presence of Renaissance Technologies as a significant shareholder, with a 5.44% stake, reflects institutional interest. Entero continues to advance its pipeline, which includes:
- Latiglutenase: A Phase 3-ready oral biotherapeutic aimed at addressing gluten-related symptoms in celiac disease.
- Capeserod: A Phase 2 selective 5-HT4 receptor partial agonist under development for gastroparesis and other GI indications.
- Adrulipase: A Phase 2 recombinant lipase enzyme for patients with exocrine pancreatic insufficiency related to cystic fibrosis and chronic pancreatitis.
The company’s focus on proprietary technologies may position it to address conditions with limited available therapies.
Market Position and Industry Context
The GI therapeutics market has a limited number of orally delivered, non-systemic options. Currently, there are no approved pharmacological treatments for celiac disease, representing a potential market for latiglutenase. Therapies for gastroparesis are primarily off-label or symptomatic, which may create opportunities for capeserod if clinical milestones are achieved. In the case of exocrine pancreatic insufficiency, existing enzyme replacement therapies face absorption variability; adrulipase may present a new alternative. Entero's late-stage development status and targeted pipeline may facilitate potential partnerships with larger pharmaceutical firms focused on GI and rare disease segments.
tl;dr
As of November 19, 2025, ENTO shares are priced at $2.87 following a 25.34% decline, alongside a delay in the Q3 10-Q linked to the GridAI acquisition's accounting and a 1-for-3 reverse stock split effective August 18, 2025. Renaissance Technologies holds 5.44% of the common stock. The company anticipates filing its Q3 10-Q by November 19, 2025, and is advancing a Phase 3 trial of latiglutenase in celiac disease along with Phase 2 studies of capeserod and adrulipase.